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Abstract: Depression is the most important nonmotor symptom in blepharospasm (BL). 
As facial expression influences emotional perception, summarized as the facial feedback 
hypothesis, we investigated if patients report fewer depressive symptoms if injections of 
botulinum neurotoxin (BoNT) include the “grief muscles” of the glabellar region, compared to 
treatment of orbicularis oculi muscles alone. Ninety BL patients were included, half of whom 
had BoNT treatment including the frown lines. While treatment pattern did not predict depressive 
symptoms overall, subgroup analysis revealed that in male BL patients, BoNT injections into the 
frown lines were associated with remarkably less depressive symptoms. We hypothesize that in 
BL patients presenting with dystonia of the eyebrow region, BoNT therapy should include frown 
line application whenever justified, to optimize nonmotor effects of BoNT denervation.
Keywords: botulinum neurotoxin, blepharospasm, depression, facial feedback, frown lines, 
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Introduction
In blepharospasm (BL) and other focal dystonias, depression is the most important non-
motor symptom, requiring adequate attention in the overall treatment strategy. While 
interaction of mood and movement disorders is complex and mutual, two sources of 
depression are unique in facial dystonia: First, as involuntary facial movements and 
impaired controllability of gestures exert a strong effect on social appearance, BL 
patients often experience stigmatization.1 Second, facial expression influences the 
emotional perception of oneself (summarized as the facial feedback hypothesis2), and 
patients with facial dystonia including forehead or eyebrows often display a mien of 
sadness, grief, or frown. These negative expressions are similar to those of patients 
with major depression, in whom activation of corrugator and procerus muscles in the 
glabellar region contributes to facial features like omega melancholicum and Veraguth’s 
folds (Figure 1).3 Interestingly, recent controlled studies provide evidence that a single 
injection of botulinum neurotoxin (BoNT) into the frown lines alleviates symptoms of 
major depression in psychiatric patients, predominantly in women.4 BoNT represents the 
treatment of choice for most facial dystonias and was shown to improve the quality of life 
with improved social functioning and mental disposition.5 Moreover, it reduces depressive 
symptoms in BL patients when injected into the orbicularis oculi muscle.5 Assuming a 
facial feedback mechanism participating in disturbances of mood in BL patients, BoNT 
treatment strategies including the injection of frown lines should improve depressive 
symptoms independently from other treatment strategies (eg, medication). The rationale 
for this study was to investigate if BL patients treated with BoNT report fewer depressive 
symptoms, when injections include the “grief muscles” of the glabellar region.
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Patients and methods
In 2014, files of all BL patients of the outpatient units for 
movement disorders and BoNT treatment at the Department 
of Ophthalmology, and the Department of Neurology, 
were considered for the study. All files were analyzed by 
the same author (JRB). Patient inclusion criteria were as 
follows: 1) idiopathic BL, 2) treatment with BoNT in 2010, 
and 3) information on depressive symptoms as measured by 
Beck’s Depression Inventory (BDI), obtained after at least 
one BoNT injection cycle. Patients were excluded from the 
study if they had 1) evidence for a nonidiopathic origin of 
BL, 2) disease onset before adulthood, 3) dystonia exceeding 
focal distribution (ie, generalized dystonia), or 4) diagnosis 
of affective or schizophrenic psychosis. In those patients, 
we analyzed treatment details retrospectively, stratifying 
patients into subgroups defined by BoNT treatment pattern: 
1) excluding frown line application: injections of orbicu-
laris oculi muscle only (“excl. frown line”); 2) including 
frown line application: injections of orbicularis oculi plus 
procerus, frontalis, or corrugator supercilii muscles (“incl. 
frown line”).
Data were analyzed using Stata (V. 13.0, StataCorp LP, 
College Station, TX, USA). BDI values were calculated as 
medians with the respective 95% CI. In subgroups, BDI 
values were compared using robust regression analysis, 
because they were not distributed normally as shown by 
Shapiro–Wilk test. Furthermore, Cook–Weisberg test 
detected heteroscedasticity in our data. Multiple regression 
analysis was undertaken to account for the effects of age 
on BDI values. A Poisson regression model was used to 
compare subgroups defined by BDI 10. P-values below 
0.05 were considered significant. Also, as patients in prior 
depression studies were mainly female,4 the effect of gender 
was calculated (multiple regression model).
The study was approved by the Ethics Committee of 
the University Hospital of Bonn (vote 156/07). All patients 
participating in the study gave written informed consent. 
Also, both patients in Figure 1 agreed to the publication of 
their images.
Results
Of 340 files screened, 90 patients were included (26%), 62 
of which were female (68%). In all patients, BoNT injection 
patterns had been chosen according to the extent of dystonic 
facial movements, and in 45 patients (50%), BoNT treatment 
included frown line application. Total BDI values did not 
differ significantly between both treatment patterns (excl. 
frown line: BDI 7 [CI, 6.1–10.1]; incl. frown line: BDI 6 
[CI, 6.1–9.5]; P=0.810). Also, prevalence of an at least mild 
disturbance of mood (BDI 10) was not different in both 
groups (excl. frown line: n=12; incl. frown line: n=16; P=0.5). 
Of the 28 patients with depressive symptoms identified here 
(31%), eight were on antidepressive medication (six with 
frown line injection and two without frown line injection; 
9% of all patients). There were no further differences in 
patients’ characteristics and demographics with regard to 
the two treatment groups as indicated in Table 1.
However, in subgroup analysis according to gender, male 
patients had significantly lower BDI values when treatment 
pattern included the frown lines (excl. frown lines n=18, 
BDI 8 [CI, 5.4–11.4]; incl. frown line: n=10, BDI 4.5 [CI, 
2.4–6.6]; P=0.03; Figure 2). In patients receiving BoNT 
application to the frown lines, the median number of injec-
tion cycles was significantly higher in female (n=23 [CI, 
23.5–41.5]), than in male patients (n=16.5 [CI, 7.6–22.2]; 
P=0.002). Also, female patients had longer disease duration 
than males (female: 11 years, range [2–44], CI, 9.34–16.43 
vs males: 4 years, range [3–16], CI, 2.99–9.41, P=0.03). 
Considering subgroup differences in potential confounders, 
calculations were controlled for age, number of BoNT treat-
ments, and disease duration. The effect of treatment pattern 
on male patients was stable, and even more obvious when 
Figure 1 Omega melancholicum and veraguth’s folds in two male patients.
Notes: (A) 73-year-old patient with major depression. (B) 65-year-old patient with blepharospasm. Dystonic movements include the frown line.
 
N
eu
ro
ps
yc
hi
at
ric
 D
ise
as
e 
an
d 
Tr
ea
tm
en
t d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
92
.1
5.
42
 o
n 
12
-M
ar
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Neuropsychiatric Disease and Treatment 2017:13 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1863
Facial feedback in blepharospasm
comparing subgroups defined by BDI 10 (frequency of 
patients with BDI 10, excl. frown line: 1.47 [95% CI, 
0.13–2.57]; incl. frown line: 0; P=0.041; not shown).
In women, no effect of treatment pattern on BDI values 
(excl. frown line: n=27, BDI 6 [CI, 5.1–10.7]; incl. frown 
line: n=35, BDI 8 [CI, 6.7–10.8]; P=0.71), or on prevalence 
of depression (BDI 10), became obvious.
Discussion
In this pilot study, BoNT injections into the frown lines 
were associated with less depressive symptoms in male BL 
patients. Our observations might be explained by the facial 
feedback hypothesis,2 which implicates a mutual influence 
of facial muscle activity and emotions. So far, this concept 
was not studied in neurological disorders, nor in BL patients, 
and mechanisms underlying the facial feedback hypothesis 
remain to be clarified. A recent research letter comparing 
data from three randomized placebo-controlled studies 
investigating the effect of BoNT on depression revealed that 
1) antidepressive response to BoNT was inversely correlated 
with the severity of glabellar frown lines; 2) severity of frown 
lines was not predictive of baseline depression severity; and 
3) improvement of depression after BoNT treatment was not 
related to a visible effect in frown line severity.6 As such, 
effects of BoNT on depression – in addition to improvement 
of vision – are feasible. Interestingly, in healthy volunteers, 
who imitated facial expressions of anger after peripheral 
denervation of frown muscles with BoNT, functional mag-
netic resonance imaging revealed a reduced activation of the 
left amygdala and associated autonomic brainstem regions.7 
This impact on the interaction of facial expression and limbic 
activation might represent another mechanism of BoNT 
denervation on depressive symptoms in BL patients. Of note, 
there are no studies investigating isolated BoNT injections 
into the frown lines, without treatment of the orbicularis oculi 
muscle. This study design would allow more detailed analysis 
of the therapeutic potential of BoNT injections on depression 
in BL patients. However, we believe that facial feedback 
mechanisms of dystonic disturbance of both – frown line and 
orbicularis oculi muscle regions – promote depression in BL 
patients, and therefore, should be treated in parallel.
Remarkably, we observed no effect of BoNT frown 
line treatment on depressive symptoms in women with BL, 
in contrast to psychiatric patients with major depression.4 
Besides the lower number of male patients in our study, 
which might restrict comparison, this observation could be 
Table 1 study sample of 90 blepharospasm patients, with subgroups according to frown line involvement
Item All patients Blepharospasm subgroups P-value
Excluding frown lines Including frown lines
Number 90 45 45
Females 68% 60% 76% 0.11F
age (years) 67 (27–86) 67 (27–86, 63–70) 67 (43–83, 64–69) 0.56M
age at disease onset (years) 60 (15–69) 60 (15–69, 53–59) 58 (30–68, 52–58) 0.61M
Disease duration (years) 9.5 (1–44) 10 (1–40, 8–13) 8 (2–44, 8–14) 0.73M
Disease severity score (Jrs) 6 (3–8) 6 (3–7, 5–6) 6 (4–8, 5.9–6.4) 0.36M
BoNT treatments (n) 19 (1–101) 18 (1–97, 18–33) 19 (1–101, 21–36) 0.44M
BDi score 7 (0–31) 7 (0–31, 6–10) 6 (0–24, 6–10) 0.91M
BDi score 10 (n) 28 (31%) 12 (27%) 16 (36%) 0.50F
antidepressants (n) 8 (9%) 2 (4%) 6 (13%) 0.26F
Notes: all results are given in median, range, and 95% ci, if not stated otherwise. FFisher’s exact test; MMann–Whitney test.
Abbreviations: BDi, Beck’s Depression inventory; BoNT, botulinum neurotoxin; Jrs, Jankovic rating scale.
Figure 2 BDI score in BL subgroups defined by gender and treatment pattern.
Notes: analysis was controlled for age, number of BoNT treatments, and disease 
duration. Data are given as median.
Abbreviations: BDi, Beck’s Depression inventory; Bl, blepharospasm; BoNT, 
botulinum neurotoxin.
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attributed to the higher number of frown line treatment cycles 
in our female patients. At the moment, we do not know if this 
reflects attenuation to the effects of BoNT on facial features 
over a longer course of treatment, which might result in 
an abatement of emotional response. In major depression, 
improvement continued over 24 weeks, even though the 
cosmetic effects of BoNT wore off at 12–16 weeks.4 Eventu-
ally, men are more susceptible to effects of facial feedback 
than women, albeit previous studies in psychiatric patients 
permit no conclusion.8 Previous studies revealed gender dif-
ferences in emotional perception, with men being better to 
recognize anger.9 Furthermore, gender-dependent differences 
in rating dynamic facial expressions were observed: men 
estimated expression of anger (not happiness) more intense, 
when a dynamic, not a static, stimulus was given, while 
women equally judged dynamic stimulus of both – anger and 
happiness – as more intense.9,10 As such, BoNT treatment might 
attenuate the dynamic nature of frowning in BL – resembling a 
mien of grief or anger – leading to a weaker reaction in men.
We are well aware that our study has several limitations. 
Interpretation of our results requires a note of caution for the 
overall interpretation, as the study is limited because of the small 
sample size and the retrospective analysis of BDI values. Also, 
we have no information on depressive symptoms, or therapy 
with antidepressants, before initiation of BoNT treatment. 
Nevertheless, as depression is common in BL patients, attention 
and assessment of mood symptoms is mandatory, regardless of 
prior treatment with conventional antidepressants.
Based on current evidence and our observations, we 
hypothesize that in BL patients presenting with dystonia of 
the eyebrow region, BoNT therapy should include frown line 
application, to optimize nonmotor effects of denervation. 
Furthermore, we believe that the robust effects observed 
in male BL patients justify to link the facial feedback 
mechanism, and its modulation by BoNT treatment, to facial 
movement disorders. However, before adjoining the facial 
feedback mechanism to the multiple facets of BoNT treat-
ment in dystonia, prospective studies are required. Also, 
gender-specific responses to stigma and impaired control-
lability of gestures in dystonia have to be addressed.
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